A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

NCT04740918 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
96
Enrollment
INDUSTRY
Sponsor class

Stopped Due to low enrollment, the Sponsor decided to prematurely terminate the study

Conditions

Interventions

Sponsor

Hoffmann-La Roche